Trials / Completed
CompletedNCT00679211
A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
A Phase II, Single-Arm, Open-Label Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study of trastuzumab emtansine (T-DM1) administered to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab emtansine [Kadcyla] | Intravenous repeating dose |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2009-09-01
- Completion
- 2011-04-01
- First posted
- 2008-05-16
- Last updated
- 2017-03-31
- Results posted
- 2013-04-23
Source: ClinicalTrials.gov record NCT00679211. Inclusion in this directory is not an endorsement.